ELUT · Elutia Inc. · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-10-01 |
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Boston Scientific released the full $8 million holdback on schedule and with no claims Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestiture The Company is now fully funded through the |
| 2026-09-10 |
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer; Dr. Michelle Williams, Chief Scientific Officer; and Matthew Ferguson, Chief |
| 2026-09-02 |
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, Matthew Ferguson, Chief Financial Officer, and Dr. |
| 2026-08-18 |
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months Divestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x NXT-41x is an antibiotic-eluting |
| 2026-08-13 |
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk The |
| 2026-08-13 |
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41x Preserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-eluting biomatrix without an equity offering NXT-41x targets the 15–20% post-operative infection |
| 2026-07-31 |
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026. |
| 2026-07-16 |
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 months Proceeds provide additional non-dilutive capital to advance NXT-41x toward anticipated clearance and targeted commercial launch in 2027 |
| 2026-06-11 |
Elutia to Present at Planet MicroCap Showcase 2026 on June 17th
GAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Dr. Michelle Williams, Chief Scientific Officer, will present and host |
| 2026-05-18 |
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on May 13, 2026 to one new employee as an inducement award under the Elutia Inc. |
| 2026-05-14 |
Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparations Brought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scale Chief Commercial Officer Pete Ligotti's initial surgeon engagement confirming significant |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-15 | H.C. Wainwright 28th Annual Global Investment Conference | Conference |
| 2026-09-10 | Lake Street Capital Markets 10th Annual Big Ideas Growth Conference | Conference |
| 2026-08-13 | Q2 FY2026 Earnings conference call (announced in 8-K) | Earnings call |
| 2026-05-18 | Elutia at the 16th Annual LD Micro Invitational | Webcast |
| 2026-05-14 | Elutia Q1 2026 Financial Results Call | Earnings call |
| 2026-03-19 | Elutia at Sidoti’s Small-Cap Virtual Investor Conference | Conference |
| 2026-03-11 | Q4 Earnings conference call (announced in 8-K) | Earnings call |
| 2026-01-13 | Elutia at the Global BioInnovation Forum | Webcast |
| 2025-11-06 | Elutia Q3 2025 Financial Results Call | Earnings call |
| 2025-10-21 | Elutia at the LD Micro Main Event XIX Conference | Conference |
| 2025-09-10 | Elutia at the H.C. Wainwright 27th Annual Global Investment Conference | Conference |
| 2025-09-04 | Elutia at the Cantor Global Healthcare Conference | Conference |
Source: https://investors.elutia.com/